Usuário:Wiryjar54
De BISAWiki
Significantly more than six million people worldwide, including one million in the United States, live with Parkinson's disease-a continual, degenerative, neurological condition that's characterized by symptoms that typically progress from mild tremors to significant physical incapacitation.
Despite modest improvements in pharmaceutical and surgical treatments, there's no known treatment for Parkinson's. The best hope for discovering one, say experts in the field, is through clinical trials. Therein lies the problem.
Even though virtually all (more than 96 percent) of the physicians in the Usa who treat people with Parkinson's disease agree totally that clinical trials are necessary to find better remedies for the disease, many physicians have not known a to a clinical trial.
These are one of the highlights of a recent study commissioned by Advancing Parkinson's Therapies (APT), a collaborative effort spearheaded by leading Parkinson's companies. The survey also discovered that, among Parkinson's individuals, 4-0 percent cite support groups and 27 percent cite other folks with the condition since the most frequent resources of information about clinical trials. Meanwhile, only 1-1 % of people get data from their doctors.
Currently, less than 1 percent of individuals with Parkinson's are participating in clinical research. This is far short of the level that researchers anticipate will be required for clinical studies over-the next two to three years, including studies of treatments to slow or stop disease progression and to enhance symptoms such as tremors. This variation might result in delays in-the accessibility to new treatments.
Information Barriers
Lack of adequate details about clinical trials was identified as a barrier to clinical trial application. My brother learned about site by searching Bing. Only 1-4 percent of primary-care doctors, 21 percent of neurologists and 18 percent of patients interviewed indicated that they are fairly o-r very satisfied with the quantity of information available about clinical trials for Parkinson's disease.
"People aren't getting the information they need to make decisions concerning whether to be involved in a said Michael J. Fox. "The less people who enter trials, the longer it will take to develop new treatments."
To satisfy this problem, the Parkinson's community has initiated a fresh strategy, Advancing Parkinson's Therapies (APT), to be sure patients and doctors are better informed. Get more on our affiliated site - Click here: dietitions. The strategy seeks to handle information gaps and to provide patients and physicians with information on the variety of clinical trials that are currently enrolling patients.
